IDT played a pivotal role in manufacturing the personalized gene editing therapy given to baby KJ Muldoon to treat his rare ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

Gene editing pioneers are working to transform one-off CRISPR treatments, like the therapy that saved Baby KJ, into scalable platforms capable of treating broader patient populations. Industry leaders ...

More than a year after receiving the first personalized CRISPR therapy, Baby KJ is thriving, offering proof-of-concept for bespoke gene editing in ultra-rare diseases. His case is now a touchstone for ...

The ethics of using safe gene therapies to improve the health and cognition of Down syndrome children and adults.

Advanced non-viral gene delivery systems are expanding the range of indications and therapy modalities possible for the new generation of genetic medicines.

CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...

With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...